Despite promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from PBMs. These insurers are frequently creating limitations to reimbursement, such as significant price criteria and approval processes that limit patient availability. Industry believe that